Added to YB: 2025-11-26
Pitch date: 2025-11-24
TEM [neutral]
Tempus AI, Inc.
-7.1%
current return
Author Info
No bio for this author
Company Info
Tempus AI, Inc. operates as a healthcare technology company. It engages in providing next generation sequencing diagnostics, polymerase chain reaction profiling, molecular genotyping, and other anatomic and molecular pathology testing to healthcare providers, pharmaceutical companies, biotechnology companies, researchers, and other third parties.
Market Cap
$12.5B
Pitch Price
$76.01
Price Target
88.00 (+25%)
Dividend
N/A
EV/EBITDA
-82.74
P/E
-59.11
EV/Sales
11.84
Sector
Life Sciences Tools and Services
Category
growth
Tempus AI (TEM): Comprehensive Investment Analysis, Valuation, and Strategic Outlook
TEM: Precision medicine data flywheel creating AI-powered oncology monopoly. Q3 2025 hit +$1.5M adj EBITDA milestone, 140% NRR proves pharma data stickiness. Ambry acquisition adds germline testing scale. DCF fair value ~$88 vs $70-85 trading range. High SBC dilution risk but fortress $764M cash balance.
Read full article (16 min)